AstraZeneca PLC (AZN)
77.34
+0.37
(+0.48%)
USD |
NASDAQ |
May 09, 12:31
AstraZeneca Net Income (TTM): 6.331B for March 31, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.331B |
| December 31, 2023 | 5.955B |
| September 30, 2023 | 5.896B |
| June 30, 2023 | 6.162B |
| March 31, 2023 | 4.704B |
| December 31, 2022 | 3.287B |
| September 30, 2022 | 2.039B |
| June 30, 2022 | -1.253B |
| March 31, 2022 | -1.063B |
| December 31, 2021 | 112.00M |
| September 30, 2021 | 1.471B |
| June 30, 2021 | 3.771B |
| March 31, 2021 | 3.977B |
| December 31, 2020 | 3.196B |
| September 30, 2020 | 2.497B |
| June 30, 2020 | 2.148B |
| March 31, 2020 | 1.522B |
| December 31, 2019 | 1.335B |
| September 30, 2019 | 2.056B |
| June 30, 2019 | 2.188B |
| March 31, 2019 | 2.408B |
| December 31, 2018 | 2.155B |
| September 30, 2018 | 2.422B |
| June 30, 2018 | 2.677B |
| March 31, 2018 | 2.804B |
| Date | Value |
|---|---|
| December 31, 2017 | 3.001B |
| September 30, 2017 | 3.542B |
| June 30, 2017 | 3.87B |
| March 31, 2017 | 3.39B |
| December 31, 2016 | 3.499B |
| September 30, 2016 | 2.465B |
| June 30, 2016 | 2.221B |
| March 31, 2016 | 2.921B |
| December 31, 2015 | 2.825B |
| September 30, 2015 | 1.696B |
| June 30, 2015 | 1.18B |
| March 31, 2015 | 1.279B |
| December 31, 2014 | 1.233B |
| September 30, 2014 | 1.03B |
| June 30, 2014 | 2.022B |
| March 31, 2014 | 2.049B |
| December 31, 2013 | 2.556B |
| September 30, 2013 | 4.587B |
| June 30, 2013 | 4.852B |
| March 31, 2013 | 5.626B |
| December 31, 2012 | 6.24B |
| September 30, 2012 | 6.153B |
| June 30, 2012 | 8.119B |
| March 31, 2012 | 8.635B |
| December 31, 2011 | 9.917B |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-1.253B
Minimum
Jun 2022
6.331B
Maximum
Mar 2024
2.817B
Average
2.342B
Median
Net Income (TTM) Benchmarks
| GSK PLC | 5.648B |
| Amgen Inc | 3.763B |
| Sanofi SA | 4.947B |
| Viking Therapeutics Inc | -93.72M |
| Fusion Pharmaceuticals Inc | -94.90M |